Abvc biopharma receives australian patent, valid until 2040, for its treatment of major depressive disorder (mdd)

Fremont, ca , feb. 12, 2024 (globe newswire) -- the company holds a u.s. patent for the same treatment via newmediawire –  abvc biopharma, inc.  (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received an australian patent, valid until 2040, application no. 2021314052, for the use of pdc-1421, a radix polygala (polygala tenuifolia willd) extract, used in the company's asset abv-1504 for the treatment of major depressive disorder (mdd).
ABVC Ratings Summary
ABVC Quant Ranking